LON:GSK

GSK Final Earnings Results & Report

GSK logo
GBX 1,842.50 +15.50 (+0.85%)
As of 11/20/2026 11:58 AM Eastern

GSK reported Final earnings on February 4, 2026. The company reported EPS of GBX 172.

Earnings Announcement Details

Quarter
Final
Report Date
Time
Before Market Opens

GSK EPS Results

Actual EPS
GBX 172
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GSK Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

GSK Final Earnings FAQ

GSK (LON:GSK) reported earnings of GBX 172 per share for Final. The report was announced on Wednesday, February 4, 2026.

GSK Earnings Headlines

GSK or UPS: Only One Gets My Dividend Dollars for the Next 20 Years
A $247 tool for $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
See More GSK Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GSK? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GSK and other key companies, straight to your email.

About GSK

GSK (LON:GSK), together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

View GSK Profile